Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Thomas Saglimbeni

Nurse Practitioner, Family New York, NY Nurse Practitioner

NPI 1396142618 CMS profile 10628561

314 W 14Th St Fl 5, New York, NY 10014

Open in the dashboard

General payments

$48,441

347 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Thomas Saglimbeni of New York, NY is reported in the CMS Open Payments database as having received $48,441 across 347 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $200 8
2023 General $18,979 144
2022 General $25,307 122
2021 General $3,955 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Saglimbeni
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Thomas Saglimbeni were reported at $0. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Thomas Saglimbeni Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $3,955 $124 $35–$379 $132
2022 $25,307 $141 $44–$430 $149
2023 $18,979 $154 $49–$476 $160
2024 $200 $165 $51–$504 $164
2025 $0 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. ViiV Healthcare Company $40,509 130 payments
  2. Gilead Sciences, Inc. $4,604 71 payments
  3. AbbVie, Inc. $431 17 payments
  4. Janssen Biotech, Inc. $383 15 payments
  5. Lilly USA, LLC $258 15 payments
  6. Merck Sharp & Dohme Corporation $231 10 payments
  7. Theratechnologies Inc. $218 6 payments
  8. Lundbeck LLC $204 10 payments
  9. Novo Nordisk Inc $164 8 payments
  10. EMD Serono, Inc. $163 10 payments
  11. Other $1,275 55 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $35,482 23 payments
  2. Food and Beverage $8,238 311 payments
  3. Travel and Lodging $3,974 8 payments
  4. Consulting Fee $543 1 payment
  5. Education $205 4 payments
Products named General payments · program years 2021–2024
  1. APRETUDE $38,754 74 payments
  2. CABENUVA $2,186 36 payments
  3. Descovy $1,915 4 payments
  4. DOVATO $1,028 22 payments
  5. SYMTUZA $483 16 payments
  6. UBRELVY $190 7 payments
  7. VRAYLAR $187 8 payments
  8. Serostim $163 10 payments
  9. PIFELTRO $161 6 payments
  10. REXULTI $158 8 payments
  11. Other $3,335 154 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

347 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record